Nimotuzumab Boosts Long-Term Survival in Head and Neck Cancer: Tata Memorial Study

A Tata Memorial Hospital study in Mumbai reveals that adding Nimotuzumab to the standard treatment for locally advanced head and neck cancer significantly improves the 10-year survival rate, without increasing late-term adverse events.

A groundbreaking study by Tata Memorial Hospital, Mumbai, has found that the addition of Nimotuzumab to the standard treatment regimen significantly enhances the 10-year overall survival rate for patients with locally advanced squamous cell carcinoma of the head and neck.

The Phase III study, which involved 536 patients, demonstrated that Nimotuzumab not only boosts progression-free survival but also preserves the quality of life for long-term survivors. Patients treated with Nimotuzumab in conjunction with radiotherapy and cisplatin displayed a 10-year overall survival rate of 33.5 percent, compared to 22.5 percent for those receiving only radiotherapy and cisplatin. The median overall survival increased from 2.78 years in the standard treatment group to 3.69 years in the Nimotuzumab group.

Experts noted that Nimotuzumab did not lead to a significant rise in late-term adverse events, underscoring its safety and tolerability. Dr. Kumar Prabhash, Head of Medical Oncology at Tata Memorial Hospital, called the findings promising for head and neck cancer patients, highlighting an increased long-term survival rate while maintaining quality of life.

Dr. Neera Gupta of Eris Lifesciences, which supported the study, noted that head and neck cancer often affects vital functions such as speaking and swallowing, compromising patients' quality of life. The study, which ran from 2012 to 2018, showed that adding Nimotuzumab to concurrent chemoradiation improves overall and progression-free survival without increasing long-term side effects.

Long-term data revealed that patients who received Nimotuzumab (NCRT) had improved overall survival rates, particularly benefiting those without human papillomavirus (HPV)-induced tumors. Importantly, Nimotuzumab is the only targeted therapy that can be combined with concurrent chemoradiation with the intent to cure for locally advanced head and neck cancer, representing a significant advancement in its management.